Clinical trial
Classification and Characterization of Patients Treated With Efalizumab for…
NCT00184366 · Norwegian University of Science and Technology, Other · Terminated
Key facts
| NCT number | NCT00184366 |
|---|---|
| Title | Classification and Characterization of Patients Treated With Efalizumab for Plaque Psoriasis |
| Official title | Classification and Characterization of Patients Suffering From Moderate to Severe Plaque Psoriasis Responding to Subcutaneous Administered Efalizumab |
| Lead sponsor | Norwegian University of Science and Technology, Other |
| Status | Terminated |
| Study type | Observational |
| Conditions | Plaque Psoriasis |
| Intervention type | Drug |
| Interventions | efalizumab |
| Enrollment | 96 |
| Start date | May 1, 2005 |
| Primary completion | May 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Sep 16, 2005 |
| Last update posted | Jan 19, 2012 |
| Countries | Norway |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: